Promega Biotech India Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 3.00 Cr
as on 16-11-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 21.44%
(FY 2023)
- Profit 81.64%
(FY 2023)
- Ebitda 81.51%
(FY 2023)
- Net Worth 1.80%
(FY 2023)
- Total Assets 14.12%
(FY 2023)
About Promega Biotech India
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Daniel Ghoca, Rajnish Bharti, and William Iii serve as directors at the Company.
- CIN/LLPIN
U51102MH2013PTC248556
- Company No.
248556
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Sep 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Promega Biotech India Private Limited offer?
Promega Biotech India Private Limited offers a wide range of products and services, including Laboratory & Lab Equipment, Science Models, Pharma & Bioanalytical Services, Pharmaceutical Services, Digestive System Drugs & Medicines, Gastrointestinal Drugs, Diagnostic Imaging & Pathology Labs, Medical Test Services.
Who are the key members and board of directors at Promega Biotech India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Daniel Ghoca  | Director | 22-Aug-2022 | Current |
Rajnish Bharti  | Whole-Time Director | 15-Dec-2014 | Current |
| William Iii | Director | 25-Sep-2013 | Current |
Financial Performance of Promega Biotech India.
Promega Biotech India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 21.44% increase. The company also saw a substantial improvement in profitability, with a 81.64% increase in profit. The company's net worth moved up by a moderate rise of 1.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Promega Biotech India?
In 2023, Promega Biotech India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Promega Biotech India?
Promega Biotech India has a workforce of 17 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Promega Biotech India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Promega Biotech India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
